In the delivery of scalable cell therapies, a fundamental step is the derivation of viable cells in vitro cell cultures. In addition to the maintenance of target cell types, cells for therapeutic use often require cell processing to acquire and develop specific characteristics.
In light of technological and methodological advancements in biological data, computational approaches for the prediction of transcription factors to drive cell conversions have been developed. However, these technologies have been limited to identifying intrinsic regulators and lacked the means to systematically identify optimal cell culture conditions. A recent publication (Kamaraj et al., Cell Systems 2020), developed and validated by researchers at Duke-NUS and Monash University, utilizes data from DNA-histone methylation modifications and protein-protein interaction network information to model the epigenetic landscape of a cell and accurately define culture conditions that can maintain the cell identity or induce cell conversion in chemically defined media.
Join the discussion with Dr. Zoe Hewitt, Project Manager of the Pluripotent Stem Cells and Engineered Cell Hub at UK Regenerative Medicine Platform, Dr. Owen Rackham, Assistant Professor at Duke-NUS Medical School and Co-Founder of Mogrify, and Dr. Rodrigo Santos, Director of Cell Technologies, Mogrify. We will cover:
- The challenges associated with the cGMP manufacture of efficacious and scalable cell therapies.
- Leveraging the power of epigenetics to drive and maintain cell identity.
- How systematic data-driven approaches, such as EpiMOGRIFY, can be implemented to enhance directed differentiation or cell conversion under cGMP-compliant cell manufacturing to support the development of scalable off-the-shelf therapies.